Lynparza (olaparib) has been recommended for use alongside abiraterone and prednisone or prednisolone for untreated hormone-relapsed metastatic prostate cancer in UK adults who cannot or will not have chemotherapy, regardless of biomarker status.
The AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) drug has been recommended in this group in a Final Draft Guidance from the UK cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE).
"This is the first time that patients with this form of prostate cancer will be able to access a PARP inhibitor without the need for a specific biomarker test"Noel Clarke, professor of Urological Oncology at The Christie, and Salford Royal Hospitals, said: “Data from the PROpel Phase III trial show that olaparib in combination with abiraterone and prednisone or prednisolone provides real benefit for men with metastatic castration-resistant prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze